This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems (MATRIX)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Biotronik SE & Co. KG
ClinicalTrials.gov Identifier:
NCT01774357
First received: January 21, 2013
Last updated: November 3, 2016
Last verified: May 2016
  Purpose
This is an observational registry study aiming to collect data on efficacy and safety of the single chamber Biotronik DX system with enhanced atrial diagnostics. The minimal follow-up period is 24 months. All analyses on the data will be done post-hoc; the study does not intend to confirm any pre-specified hypotheses.

Condition
Atrial Fibrillation Tachycardia ICD Therapy Thromboembolic Events Heart Failure

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems

Resource links provided by NLM:


Further study details as provided by Biotronik SE & Co. KG:

Primary Outcome Measures:
  • Frequency and types of AF-related complications [ Time Frame: 24 months ]
  • Time to occurrence of first AF-related complication [ Time Frame: 24 months ]
  • Time to AF-related intervention after detection of de novo or worsening AF [ Time Frame: 24 months ]

Secondary Outcome Measures:
  • Frequency and type of complications related to implantation [ Time Frame: 24 months ]
  • Frequency and type of lead-related complications [ Time Frame: 24 months ]
  • All-cause mortality [ Time Frame: 24 months ]
  • Cardiovascular hospitalization with days in hospital [ Time Frame: 24 months ]
  • Significance of AF in acute decompensation of heart failure [ Time Frame: 24 months ]
  • Interventions based on Home Monitoring information regarding AF [ Time Frame: 24 months ]

Enrollment: 2058
Study Start Date: January 2013
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with an indication for implantation of a single chamber ICD (primary or secondary prevention) according to current guidelines and after implantation of a BIOTRONIK Lumax 540 VR-T DX ICD with Linoxsmart S DX or successor single chamber DX system within 90 days prior to enrollment
Criteria

Inclusion Criteria:

  • Indication for implantation of a single chamber ICD (primary or secondary prevention) according to current guidelines
  • Implanted with a BIOTRONIK Lumax 540 VR-T DX ICD with Linoxsmart S DX or successor single chamber DX system within 90 days prior to enrollment
  • Written informed consent, willingness and ability to comply with the protocol

Exclusion Criteria:

  • Age < 18 years
  • Any limitation to contractual capability
  • Female patients who are pregnant or breast feeding or plan a pregnancy during the course of the study
  • Known active malignant disease or recovered from malignant disease within 2 years prior to enrollment
  • Simultaneous participation in another study
  • Life expectancy < 2 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01774357

Locations
Germany
Herzzentrum Leipzig
Leipzig, Sachsen, Germany, 04289
Sponsors and Collaborators
Biotronik SE & Co. KG
Investigators
Principal Investigator: Gerhard Hindricks, Prof. Dr. Herzzentrum Leipzig, Germany
  More Information

Responsible Party: Biotronik SE & Co. KG
ClinicalTrials.gov Identifier: NCT01774357     History of Changes
Other Study ID Numbers: TA102
Study First Received: January 21, 2013
Last Updated: November 3, 2016
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Heart Failure
Atrial Fibrillation
Tachycardia
Thromboembolism
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases

ClinicalTrials.gov processed this record on June 28, 2017